U.S. Markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,895.66
    +431.38 (+1.02%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     
  • Oops!
    Something went wrong.
    Please try again later.

Moderna's COVID-19 Shot Provides Over 90% Effectiveness Six Months After Second Dose, Boosters Can Potentially Fight Against Variants

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Just a day before Moderna Inc’s (NASDAQ: MRNA) second annual Vaccines Day, the company has posted an update on its COVID-19 Vaccine Program, including a 6-month look at the COVID-19 shot and new preclinical data that suggest its booster candidates stand a chance against new variants.

  • COVID-19 Vaccine Additional Data: An updated review of 900-plus COVID-19 cases from the Phase 3 COVE study confirms the jab is more than 90% effective against all cases and over 95% effective against severe cases.

  • According to results published in the New England Journal of Medicine, an NIH-led Phase 1 study in 33 participants showed that antibodies persisted six months after the second dose.

  • Moderna believes efficacy starts in two weeks after the second dose.

  • Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) partnered jab demonstrated six months after the second dose an overall efficacy rate of 91.3%.

  • Variant-Specific Booster Candidates: Moderna’s variant-specific booster dubbed mRNA-1273.351, designed to target the B.1.351 mutation first identified in South Africa, elicited neutralizing titers against the variant that were comparable to those produced against the original virus.

  • mRNA-1273.211, a combination of mRNA-1273.351 and Moderna’s already authorized vaccine, also increased neutralizing titers against variants.

  • The company said its results are preliminary. Moderna noted it would share updated data on efficacy against asymptomatic infection and the persistence of antibodies throughout the year.

  • Additional Studies Update: Phase 2/3 TeenCOVE study is fully enrolled with about 3,000 participants between the ages of 12 and 17 in the U.S. That trial will assess a 100 µg dose of the vaccine.

  • Meanwhile, the Phase 2/3 KidCOVE study is still recruiting children between 6 months and 11 years old. The company hopes to enroll 6,750 healthy participants in the two-part dose-escalation study.

  • Supply Update: As of April 12, Moderna had shipped out 132 million doses globally, including about 117 million to the U.S.

  • Roughly 88 million doses were delivered to the U.S. in Q1, in addition to about 14 million elsewhere. Plans are in place to ramp up the company’s ex-US supply chain.

  • Moderna says it’s on track to deliver 100 million doses to the U.S. by the end of May and another 100 million by the end of July.

  • Price Action: MRNA shares are up 2.6% at $153.6 in the premarket on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.